GC
NVO

GFG Capital’s Novo Nordisk NVO Stock Holding History

GFG Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,321
Closed -$91.2K – 256
2025
Q2 		$91.2K Buy
+1,321
New +$89.9K 0.03% 85
2025
Q1 		– Sell
-2,629
Closed -$226K – 121
2024
Q4 		$226K Buy
+2,629
New +$284K 0.06% 102
2024
Q3 		– Sell
-2,048
Closed -$292K – 126
2024
Q2 		$292K Buy
2,048
+95
+5% +$12.6K 0.08% 102
2024
Q1 		$251K Sell
1,953
-59
-3% -$7.02K 0.06% 114
2023
Q4 		$208K Buy
+2,012
New +$199K 0.06% 123

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GFG Capital's NVO Position: Q3 2025 in Review

GFG Capital sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 1,321 shares — an estimated $91.2K sold.

GFG Capital first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $292K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • GFG Capital reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • GFG Capital sold 1,321 Novo Nordisk shares in Q3 2025, an estimated $91.2K.
  • GFG Capital first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • GFG Capital's Novo Nordisk position peaked at $292K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.